Spring Creek Capital’s West Pharmaceutical WST Stock Holding History

Spring Creek Capital’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-12,386	Closed	-$1.23M	–	686
2018 Q2	$1.23M	Buy	+12,386	New	+$1.14M	0.14%	80

Other funds holding WST

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Spring Creek Capital's WST Position: Q3 2018 in Review

Spring Creek Capital sold out of West Pharmaceutical (WST) in Q3 2018, closing a stake of 12,386 shares — an estimated $1.23M sold.

Spring Creek Capital first reported a position in WST in Q2 2018 and held it in 1 quarter. The position peaked at $1.23M in Q2 2018. 354 funds tracked by Wall St. Rank hold WST as of Q3 2018.

Spring Creek Capital reported no remaining West Pharmaceutical position as of Q3 2018 after selling out during the quarter.
Spring Creek Capital sold 12,386 West Pharmaceutical shares in Q3 2018, an estimated $1.23M.
Spring Creek Capital first reported a position in West Pharmaceutical in Q2 2018 and held it in 1 quarter.
Spring Creek Capital's West Pharmaceutical position peaked at $1.23M in Q2 2018.
354 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2018.

Based on Spring Creek Capital's 13F filing for Q3 2018, filed 13 Nov 2018.